#EULAR2022 OP0135: German RABBIT 🐇 Registry: ⭐️ Observational, 46% Tofa, 54% Bari No increased rate of CVD in JAK vs TNF inhibitor 🚨Unlike the ORAL Surveillance @RheumNow https://t.co/O4IXg22Ybc

#EULAR2022 OP0136: PROTECT-RA Cohort - 150 pts established RA Cholesterol loading capacity (CLC) on macrophages ⭐️High CLC correlates with CV events ⭐️bDMARD use affects CLC @RheumNow https://t.co/9ngaH9yUI7

RABBIT registry and MACE in RA No difference between *JAKi (Tofa and Bari) and *TNFi in both unselected and high CV risks patients. 🧨 different than ORAL surveillance but Observational and overall Low incidence (28 events). #EULAR2022 @RheumNow OP0135 https://t.co/o8rngHrwQF

The CONSUL study @ProftDr showed there was no significant difference in Celecoxib(CEL)+Golimumab (GOL) vs GOL alone. The mSASSS change was 1.1 vs 1.7, p=0.79 between the 2 groups. The combination may be clinically relevant in high-risk progressors #EULAR2022 @RheumNow OP0018 https://t.co/AUOL7IDx9L

MIRACLE study: High or Low dose MTX w/ ADA in eRA? ✨ LOWd (6-8mg/w) 38.4% non-inferior to HIGHd (>10mg/w) 44.8% ✨But safety profile looks better 9.1% vs 22.1% 👀 Are you already looking for minimal dose of MTX in patients treated w/ biologics? #OP0062 @Rheumnow #EULAR2022 https://t.co/dq0EIKSnOe

Occupational and non occupational silica exposure in RA increases ILD. At home exposure was higher in women due to cleaning - talc, laundry detergents, etc. Maybe some items should be banned or people protected - ? Masks. V interesting #OP0006 @RheumNow #EULAR2022 @eular_org